Education
About Us
Working with TipRanks
Follow Us
Mirum Pharmaceuticals (MIRM)
:MIRM
MIRM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$36.88 - $78.10
Previous CloseN/A
Volume92.82K
Average Volume (3M)756.96K
Market Cap
$3.70B
Enterprise Value$2.54B
Total Cash (Recent Filing)$304.55M
Total Debt (Recent Filing)$318.90M
Price to Earnings (P/E)―
Beta0.77
Next Earnings
Nov 12, 2025EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding50,237,648
10 Day Avg. Volume783,981
30 Day Avg. Volume756,963
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.69
Enterprise Value/Revenue5.93
Enterprise Value/Gross Profit7.50
Enterprise Value/Ebitda-135.43
Forecast
1Y Price Target
$81.67Price Target Upside12.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
Bulls Say, Bears Say
Bulls Say
Pipeline GrowthVolixibat is undergoing two late-stage trials in primary sclerosing cholangitis and primary biliary cholangitis, which could initiate the next phase of growth for Mirum.
Product AdoptionLivmarli, Mirum's lead product, has seen favorable adoption and uptake across patient groups.
Revenue GrowthLivmarli's growth prospects, supported by multiple upside levers and a steady stream of revenues, largely underpin the company's current valuation.
Bears Say
Market CompetitionEven with competition, volixibat is seen as well-positioned in large rare diseases, with its potential to differentiate on efficacy and benefit from market developments.
Mirum Pharmaceuticals News
MIRM FAQ
What was Mirum Pharmaceuticals’s price range in the past 12 months?
Mirum Pharmaceuticals lowest stock price was $36.88 and its highest was $78.09 in the past 12 months.
What is Mirum Pharmaceuticals’s market cap?
Mirum Pharmaceuticals’s market cap is $3.70B.
When is Mirum Pharmaceuticals’s upcoming earnings report date?
Mirum Pharmaceuticals’s upcoming earnings report date is Nov 12, 2025 which is in 33 days.
How were Mirum Pharmaceuticals’s earnings last quarter?
Mirum Pharmaceuticals released its earnings results on Aug 06, 2025. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.326 by $0.206.
Is Mirum Pharmaceuticals overvalued?
According to Wall Street analysts Mirum Pharmaceuticals’s price is currently Undervalued.
Does Mirum Pharmaceuticals pay dividends?
Mirum Pharmaceuticals does not currently pay dividends.
What is Mirum Pharmaceuticals’s EPS estimate?
Mirum Pharmaceuticals’s EPS estimate is -0.15.
How many shares outstanding does Mirum Pharmaceuticals have?
Mirum Pharmaceuticals has 50,237,648 shares outstanding.
What happened to Mirum Pharmaceuticals’s price movement after its last earnings report?
Mirum Pharmaceuticals reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.326. Following the earnings report the stock price went up 12.043%.
Which hedge fund is a major shareholder of Mirum Pharmaceuticals?
Currently, no hedge funds are holding shares in MIRM
Mirum Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$81.67 (12.11% Upside)
$81.67 (12.11% Upside)
Blogger Sentiment
Bullish
MIRM Sentiment 70%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 8.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.2%
Last 30 Days ▲ 3.8%
Last 30 Days ▲ 3.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
95.03%
12-Months-Change
Fundamentals
Return on Equity
-24.19%
Trailing 12-Months
Asset Growth
9.85%
Trailing 12-Months
Company Description
Mirum Pharmaceuticals
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
MIRM Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong performance by Mirum Pharmaceuticals, highlighted by significant revenue growth and positive pipeline developments. While there are challenges such as high operating expenses and variability in international sales, the positive aspects significantly outweigh the negatives.View all MIRM earnings summariesMIRM Stock 12 Month Forecast
Average Price Target
$81.67
▲(12.11% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
Catalyst Pharma
―
Ultragenyx Pharmaceutical
―
ImmunityBio
―
Apellis Pharmaceuticals
―
Ownership Overview
9.02% Insiders
25.74% Mutual Funds
0.39% Other Institutional Investors
52.22% Public Companies and
Individual Investors